Bausch Health(US:BHC)2026-02-18 23:10Revenue Growth - Revenues for 2025, 2024, and 2023 were $10,266 million, $9,625 million, and $8,757 million, respectively, indicating a growth of approximately 6.7% from 2024 to 2025[28] - The Xifaxan product generated revenues of $2,212 million, $1,993 million, and $1,810 million for 2025, 2024, and 2023, respectively, reflecting a year-over-year increase of 11% from 2024 to 2025[29] - In 2025, the U.S. accounted for approximately 60% of total revenues, while China accounted for about 5%[80] - Cencora Inc. contributed 18% of total revenue in 2025, followed by McKesson Corporation at 16% and Cardinal Health, Inc. at 14%[80] Product Development and Innovation - The company completed the acquisition of DURECT Corporation in September 2025, focusing on epigenetic therapies for severe illnesses, with Larsucosterol receiving Breakthrough Therapy designation from the FDA[30][31] - The company has approximately 80 R&D projects in its pipeline, supported by around 1,400 dedicated R&D and quality assurance employees across 25 facilities[43] - The launch of CABTREO, a fixed-dose combination topical treatment for acne, occurred in the U.S. in Q1 2024, with a Canadian launch in October 2024[41] - The company is in the process of submitting a New Drug Application for Lumify next generation in the first half of 2026, indicating a focus on innovation in eye care[45] Regulatory Compliance - The company is subject to extensive regulations governing the research, development, testing, approval, and marketing of pharmaceutical products and medical devices, requiring substantial time and financial resources[51] - The FDA approval or marketing clearance must be obtained prior to human use in the U.S., with similar requirements in Canada and the EU, necessitating preclinical studies and clinical trials[52] - The company faces periodic audits by regulatory agencies, including the FDA and Health Canada, to ensure compliance with manufacturing regulations and good manufacturing practices[57] - The company must comply with various health care marketing and fraud regulations, including the federal False Claims Act and the Anti-Kickback Statute, which impose civil and criminal liabilities for non-compliance[58] - The company is required to have comprehensive compliance programs and must report any "transfer of value" to prescribers under the Physician Payment Sunshine Act[59] - The company is subject to the General Data Protection Regulation (GDPR) in the EU, which imposes strict obligations on the processing of personal data, with potential fines of up to 4% of global annual revenue[65] - The Personal Information Protection Law (PIPL) in China, effective from November 2021, regulates personal information protection and imposes specific requirements for transferring personal data outside China[68] Market and Pricing Dynamics - The success of the company's products may depend on governmental and third-party payor reimbursement, with increasing pressures to limit or regulate prices in significant markets[69] - The IRA allows the U.S. government to negotiate prices for select high-cost Medicare drugs starting in 2026, which may materially impact the company's operations[73] - The negotiated price for Xifaxan will take effect on January 1, 2027, and is expected to negatively impact revenues primarily in 2027 due to anticipated generic competition beginning in 2028[73] - The company is subject to price control restrictions on its pharmaceutical products in many countries, impacting average realized prices and potentially leading to discounts and rebate obligations[70] - Legislative efforts to control drug costs may lead to new mandatory rebates and discounts, impacting pricing strategies[75] - The company faces increased competition from generic manufacturers as patents expire, which could lead to significant price reductions[85] Manufacturing and Operations - Approximately 28% of product sales for 2025 were produced by third-party manufacturers under manufacturing arrangements[91] - The company operates 37 manufacturing sites worldwide, with 25 being Bausch + Lomb facilities[87] - The company is subject to extensive environmental regulations, which could result in significant liabilities if compliance is not maintained[79] Employee and Safety Metrics - As of December 31, 2025, the company had approximately 20,300 employees, with 13,000 in Bausch + Lomb and 10,300 in production[94] - The Lost Time Incident Rate for Bausch Health was 0.8 recorded cases per 100 employees in 2025, slightly above the industry average of 0.5[96] - Bausch + Lomb's Days Away Rate (DAR) was 5.5 in 2025, meeting its goal of not exceeding 6 and significantly lower than the industry standard DAR of 22[97] Financial Position and Risks - As of December 31, 2025, the company had $13,553 million in fixed rate debt and $6,679 million in variable rate debt[580] - A 1% change in foreign currency exchange rates would have impacted the shareholders' deficit by approximately $43 million as of December 31, 2025[577] - If interest rates were to increase by 100 basis points, the fair value of the issued fixed rate debt would decrease by approximately $350 million[580] - The company is subject to various loss contingencies, which may materially affect its results of operations and financial condition[629] - The effective tax rate may change based on the mix of activities and income earned under intercompany arrangements, potentially impacting the company's financial results[630] Goodwill and Impairment - Goodwill impairments were $145 million during 2025 related to the Generics reporting unit, with no impairments in 2024 and $493 million in 2023[597] - The quantitative fair value test for the Generics reporting unit utilized a long-term growth rate of 1.0% and a discount rate of 10.25%, resulting in a goodwill impairment of $91 million as of October 1, 2023[612] - The Dermatology reporting unit recognized a goodwill impairment of $151 million based on a long-term growth rate of 0.0% and a discount rate of 10.75% during the third quarter of 2023[604] - The Neuroscience reporting unit had remaining goodwill of $1,170 million as of December 31, 2025, with no impairment recognized after a quantitative fair value test showing a fair value exceeding carrying value by approximately 100%[610] - The fair value of the Dermatology reporting unit exceeded its carrying value by more than 50% during the annual goodwill impairment test as of October 1, 2024, resulting in no impairment[605] - The Generics reporting unit recognized a goodwill impairment of $145 million as its carrying value exceeded its fair value as of October 1, 2025[614] - The International reporting unit's fair value exceeded its carrying value by more than 45% as of October 1, 2023, indicating no impairment to goodwill[615] - The Salix reporting unit had remaining goodwill of $3,159 million as of December 31, 2025, with no impairment recognized after the quantitative fair value test[617] - A preliminary quantitative goodwill analysis for the Salix reporting unit anticipates an impairment charge of approximately $1,400 million in Q1 2026 due to failed Phase 3 clinical trials[618] - Bausch + Lomb's reporting units had fair values exceeding their carrying values by more than 25% as of October 1, 2023, resulting in no impairment to goodwill[619] - The quantitative fair value testing procedures performed as of October 1, 2025 represented approximately $4,556 million, or 40% of the total goodwill balance of $11,271 million as of December 31, 2025[627] - Market conditions and trends were continuously monitored, with no events indicating that the fair value of any reporting unit might be below its carrying value as of December 31, 2025[623] - The quantitative fair value tests utilized long-term growth rates of 3.0% and discount rates ranging from 10.00% to 11.50% for Bausch + Lomb's reporting units[622]